AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up

Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in ​the company and collaborate on a ‌series of studies testing their cancer treatments together.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。